유전체학 시장 예측(-2030년) : 제품, 서비스, 기술, 용도, 최종사용자, 지역별 세계 분석

According to Stratistics MRC, the Global Genomics Market is accounted for $46.2 billion in 2023 and is expected to reach $118.4 billion by 2030 growing at a CAGR of 14.4% during the forecast period. The study of an organism's whole genome, or collection of genes, is at the center of the scientific discipline known as genomics. All genes, their roles, interactions, and the structure and arrangement of the DNA within an organism are analyzed and characterized. It also has many applications in fields including medicine, agriculture, evolutionary biology, and more. Techniques like DNA sequencing and bioinformatics are frequently used in genomic research to collect and interpret genetic data.

According to the National Cancer Institute, by 2040, the number of new cancer cases is expected to rise by 29.5 million, while cancer-related fatalities will rise by 16.4 million.

Market Dynamics:

Driver:

Genomics in specialty medicine

Numerous pharmaceutical firms are making growing investments in the study of tailored medicine. With the use of personalized medicine, doctors can pinpoint a patient's precise needs and then prescribe medications and therapies in response. Better healthcare results are ensured by this strategy. Numerous possibilities for market participants will arise as a result of the growth of the customized medicine business.

Restraint:

Delicate instrument handling

Gene editing, amplification, sequencing, and multiplexing are just a few of the complicated and delicate techniques used in genomic investigations. These techniques include the use of sophisticated tools, including sequencers, centrifuges, analyzers, liquid handling equipment, and PCR and microarray equipment. Therefore, extreme caution must be used when using all of the devices. Handling such delicate devices is a significant market growth inhibitor.

Opportunity:

Increasing cancer rates

The prevalence of cancer and the growing use of next-generation sequencing in cancer research are important drivers of the market's expansion. The way cancer is identified and treated is changing as a result of genomics. The methods for detecting cancer from a blood sample are getting better because to genome research. Genomic research has led to a rise in hereditary cancer screening tests. As a result, the market is expanding due to the rising incidence of cancer and the effective use of genomics in cancer diagnosis and treatment.

Threat:

Cost and affordability

Despite improvements in DNA sequencing technology, whole genome sequencing and comprehensive genomic profiling are among the most costly genomic tests and analyses. The broad use of genomics in clinical practice is constrained by the high costs involved with genetic testing and interpretation, particularly in locations with limited resources or for people with poor financial means. The availability and accessibility of genomic goods and services are also impacted by financial a factor, which restrains the expansion of the industry.

COVID-19 Impact:

The early stage of the pandemic saw a little negative rise in the COVID-19 effect. This was caused by a decline in personalized medicine, cancer research, and other research efforts. The epidemic also caused difficulties in delivering post-sales services and the temporary closure of some academic institutions, which disrupted the market as a whole. To examine viral genetic material, laboratories employed the polymerase chain reaction (PCR) and next-generation sequencing (NGS).

The pathway analysis segment is expected to be the largest during the forecast period

The pathway analysis segment is expected to be the largest during the forecast period. One of the most rapidly expanding uses of route analysis is the creation of next-generation therapies. Since the advent of clinical genomics and tailored treatments, pathway-based analysis has drawn increased interest. This is mostly due to the assistance provided by genetics and individualized medicines for the in-depth investigation of the capacity to navigate illness networks and signaling pathways.

The research institutes segment is expected to have the highest CAGR during the forecast period

The research institutes segment is expected to have the highest CAGR during the forecast period. Researchers with a focus on genomics, financing from public and private foundations, and business partnerships are some of the reasons that contribute to the segment's dominance in the market for genomics services. Additionally, the research institutes category is anticipated to grow faster throughout the projection period due to collaborations with other academic institutions, hospitals, and biotechnology firms.

Region with largest share:

North America is projected to hold the largest market share during the forecast period due to the support of research institutes and pharmaceutical giants. Due to the effects of genetic expression on human health, genomics is now a crucial component of all illness research and therapeutic development. Additionally, the presence of cutting-edge healthcare infrastructure, which supports the expansion of technical advancements in this industry, and rising demand for biotechnology services in the area are anticipated to support regional growth.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period due to increased demand for genomics applications in diagnostics and the growing demand for novel therapeutic drugs to fight the increased incidence of diseases. Additionally, the rising incidence of chronic illnesses like cancer, greater government funding for research, and growing consumer awareness all contribute to the expansion of regional markets.

Key players in the market

Some of the key players in Genomics market include: BGI Genomics, Myriad Genetics, Inc., Agilent Technologies, Quest Diagnostics Incorporated, Thermo Fisher Scientific, Inc., Eurofins Scientific, Danaher Corporation, Eppendorf AG, Bio-Rad Laboratories, Inc., Color Genomics, Inc., Agilent Technologies, F. Hoffmann-La Roche Ltd., GE Healthcare, Illumina, Inc., Oxford Nanopore Technologies, Quest Diagnostics Incorporated, Pacific Biosciences of California, Inc. and Color Health, Inc.

Key Developments:

In June 2023, BGI Genomics was recognized as the GB/T 35770-2022/ISO 37301 Compliance Management System accreditation-approved company, after the extensive evaluation of BSI, a global testing, standardization, and certification authority.

In June 2023, Myriad Genetics and The University of Texas MD Anderson Cancer Center announced their collaboration aimed at metastatic renal cell carcinoma treatment selection and response research and incorporating Myriad's minimal residual disease testing platform based on whole genome sequencing.

In April 2023, Bio-Rad Laboratories, Inc. pivoted their measurable residual disease (MRD) genomics research via a half dozen collaborations with companies and institutions to launch their new QX600™ Droplet Digital™ PCR System.

Products Covered:

• Consumables & Reagents
• Instruments/Systems/Software
• Other Products

Services Covered:

• Core Genomics Services
• Computational Services
• NGS-based Services
• Biomarker Translation Services
• Other Services

Technologies Covered:

• Epigenomics
• Biomarker Discovery
• Pathway Analysis
• Functional Genomics
• Other Technologies

Applications Covered:

• Agriculture and Animal research
• Drug Discovery and Development
• Other Applications

End Users Covered:

• Pharmaceutical & Biotechnology Companies
• Hospitals
• Diagnostics Centers
• Academic Institutes
• Clinical Research
• Healthcare Facilities
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 Technology Analysis
• 3.7 Application Analysis
• 3.9 End User Analysis
• 3.10 Emerging Markets
• 3.11 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Genomics Market, By Product

• 5.1 Introduction
• 5.2 Consumables & Reagents
• 5.3 Instruments/Systems/Software
• 5.4 Other Products

6 Global Genomics Market, By Service

• 6.1 Introduction
• 6.2 Core Genomics Services
• 6.3 Computational Services
• 6.4 NGS-based Services
• 6.5 Biomarker Translation Services
• 6.6 Other Services

7 Global Genomics Market, By Technology

• 7.1 Introduction
• 7.2 Epigenomics
  • 7.2.1 Chromatin Immunoprecipitation (ChIP & ChIP-Seq)
  • 7.2.2 Chromatin Accessibility Assays
  • 7.2.3 High-Resolution Melt (HRM)
  • 7.2.4 Bisulfite Sequencing
  • 7.2.5 Methylated DNA Immunoprecipitation (MeDIP)
  • 7.2.6 Microarray Analysis
• 7.3 Biomarker Discovery
  • 7.3.1 Real-time PCR
  • 7.3.2 Mass Spectrometry
  • 7.3.3 Microarray Analysis
  • 7.3.4 Statistical Analysis
  • 7.3.5 DNA Sequencing
  • 7.3.6 Bioinformatics
• 7.4 Pathway Analysis
  • 7.4.1 Microarray Analysis
  • 7.4.2 Proteomics Tools
  • 7.4.3 Real-time PCR
  • 7.4.4 Bead-Based Analysis
• 7.5 Functional Genomics
  • 7.5.1 Real-Time PCR
  • 7.5.2 Mutational Analysis
  • 7.5.3 RNA Interference
  • 7.5.4 SNP Analysis
  • 7.5.5 Transfection
  • 7.5.6 Microarray Analysis
• 7.6 Other Technologies

8 Global Genomics Market, By Application

• 8.1 Introduction
• 8.2 Agriculture and Animal research
• 8.3 Drug Discovery and Development
• 8.4 Other Applications
  • 8.4.1 Biofuel Research
  • 8.4.2 Marine Research
  • 8.4.3 Food Industry
  • 8.4.4 Forensics

9 Global Genomics Market, By End User

• 9.1 Introduction
• 9.2 Pharmaceutical & Biotechnology companies
• 9.4 Hospitals
• 9.5 Diagnostics Centers
• 9.6 Academic Institutes
• 9.8 Clinical Research
• 9.9 Healthcare Facilities
• 9.9 Other End Users

10 Global Genomics Market, By Geography

• 10.1 Introduction
• 10.2 North America
  • 10.2.1 US
  • 10.2.2 Canada
  • 10.2.3 Mexico
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 Italy
  • 10.3.4 France
  • 10.3.5 Spain
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 New Zealand
  • 10.4.6 South Korea
  • 10.4.7 Rest of Asia Pacific
• 10.5 South America
  • 10.5.1 Argentina
  • 10.5.2 Brazil
  • 10.5.3 Chile
  • 10.5.4 Rest of South America
• 10.6 Middle East & Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 UAE
  • 10.6.3 Qatar
  • 10.6.4 South Africa
  • 10.6.5 Rest of Middle East & Africa

11 Key Developments

• 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 11.2 Acquisitions & Mergers
• 11.3 New Product Launch
• 11.4 Expansions
• 11.5 Other Key Strategies

12 Company Profiling

• 12.1 BGI Genomics
• 12.2 Myriad Genetics, Inc.
• 12.3 Agilent Technologies
• 12.4 Quest Diagnostics Incorporated
• 12.5 Thermo Fisher Scientific, Inc.
• 12.6 Eurofins Scientific
• 12.7 Danaher Corporation
• 12.7 Eppendorf AG
• 12.9 Bio-Rad Laboratories, Inc.
• 12.10 Color Genomics, Inc.
• 12.11 Agilent Technologies
• 12.12 F. Hoffmann-La Roche Ltd.
• 12.12 GE Healthcare
• 12.14 Illumina, Inc.
• 12.15 Oxford Nanopore Technologies
• 12.16 Quest Diagnostics Incorporated
• 12.17 Pacific Biosciences of California, Inc.
• 12.17 Color Health, Inc.